Full-Time

Operations Supervisor

Logistics & Cold Chain

Updated on 9/9/2026

Orca Bio

Orca Bio

201-500 employees

Develops and commercializes safer cell therapies

Compensation Overview

$80k - $110k/yr

+ Pre-IPO equity + Annual bonus

Sacramento, CA, USA

In Person

May require work at either Sacramento facility, with scheduled overtime, weekends, or holidays based on business needs.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
Incident Response
Supply Chain Management

Get referred to Orca Bio

See people who can refer or advise you

Requirements
  • A bachelor's degree and 5–7 years of relevant logistics or supply chain experience.
  • At least 2 years of direct people-management experience, including hiring, scheduling, and performance management.
  • Proven success leading logistics and/or cold chain operations, preferably in a regulated environment.
  • Working knowledge of chain-of-custody requirements and cold chain handling of biological or pharmaceutical materials.
  • Proficiency in logistics tracking systems or software.
  • Ability to meet cleanroom gowning requirements and wear full gowning for extended periods as needed.
  • Ability to work at either Orca Bio Sacramento location based on operational needs.
  • Ability to work scheduled overtime, weekends, or holidays based on business needs.
Responsibilities
  • Lead, develop, and retain a cross-trained logistics and cold chain team while setting expectations, standards, and accountability.
  • Be present and available during active runs, handoffs, coverage crunches, and other periods requiring leadership presence.
  • Balance workload across the Sacramento sites based on batch volume and operational demand.
  • Run structured handoffs with the counterpart Operations Supervisor.
  • Own vein-to-vein performance, monitor key performance indicators, identify trends, and drive corrective and preventive actions.
  • Oversee real-time coordination of active courier runs, including tracking flights, weather, and disruptions.
  • Direct disruption and incident response, including flight and hotel rebooking, itinerary and Transportation Security Administration letter re-issuance, and third-party negotiations.
  • Partner with manufacturing, case management, and clinical scheduling to triage delays affecting batch and delivery timelines.
  • Ensure cold chain readiness, including Credo and dry-shipper charging, preparation, qualification, and recirculation.
  • Oversee Good Manufacturing Practice packing, asset checkout and batch assignment in TrakSYS, final handover, chain-of-custody execution, and shipping-condition confirmation.
  • Maintain qualified shipper inventory and asset availability for forecasted batch demand.
  • Ensure temperature monitoring, data upload, and excursion response are completed promptly and documented correctly.
  • Ensure chain-of-custody documentation, temperature data, and return-of-materials tracking are complete, accurate, and compliant.
  • Maintain compliance with Good Manufacturing Practice/current Good Manufacturing Practice, International Air Transport Association, Department of Transportation, and applicable transport and cold chain regulations.
  • Partner with Quality on deviations, corrective and preventive actions, and audit readiness, and ensure standard operating procedures are current and followed.
  • Update delivery times in OrcaLink and ensure vein-to-vein data capture for key performance indicator reporting.
  • Partner with the Logistics Program Manager to own the Orca Porter courier program, including courier scheduling, flight and travel logistics, and performance tracking and optimization.
  • Partner in leading third-party logistics courier implementation, vendor relationships, and issue resolution.
  • Review and approve courier invoices and manage cost and performance across airlines, travel providers, and third-party logistics providers.
  • Oversee commercial site feasibility assessments and dry-run support for new and existing treatment centers.
  • Evaluate and improve logistics and cold chain workflows to support operational scalability and commercial growth.
  • Contribute to and maintain training programs, standard operating procedures, and qualification frameworks.
  • Support capacity planning, tooling, and process changes that increase reliability and throughput.
  • Partner with Manufacturing, Quality, Clinical Scheduling, Commercial Case Management, and external donor and recipient organizations.
  • Represent Logistics and Cold Chain in operational planning, readiness reviews, and cross-functional projects.
  • Directly manage Logistics Specialists and oversee the cold chain/packaging operations hourly team.
  • Own hiring, onboarding, scheduling, timekeeping approvals, performance management, coaching, and career development for the team.
  • Maintain team coverage and escalation paths that protect vein-to-vein timelines.
  • Ensure team members maintain current training and qualifications and that records are audit-ready.
  • Serve as an escalation point for non-routine transport and cold chain issues.
Desired Qualifications
  • A Bachelor of Science in biology, life sciences, supply chain, or logistics.
  • Cell or gene therapy, biologics, or other time- and temperature-sensitive supply chain leadership experience.
  • Experience managing a 24/7 or multi-shift operation with on-call coverage.
  • Cold chain qualification and packaging operations experience, including Credo, dry shippers, temperature monitoring, TrakSYS, or equivalent manufacturing execution or asset systems.
  • Knowledge of International Air Transport Association, Department of Transportation, and Good Manufacturing Practice/current Good Manufacturing Practice compliance, and experience partnering with Quality on deviations and corrective and preventive actions.
  • Courier or third-party logistics program management experience.
  • Continuous improvement, Kaizen, standard operating procedure development, and scaling operations in a startup or high-growth environment.

Orca Bio develops and commercializes cell therapies to improve outcomes for patients. It works by researching, developing, and producing therapies that use the body’s own cells to treat diseases, with products sold to healthcare providers who administer them to patients. The company aims to enhance the safety and effectiveness of cell therapies, making treatments more reliable for conditions that lack good options. Orca Bio differentiates itself through its focus on delivering safer, more effective therapies and by fostering a strong team culture with active stakeholder communication, including a regularly updated newsroom. Overall, its goal is to expand access to improved cell therapies and become a leading player in the cell therapy market.

Company Size

201-500

Company Stage

Series F

Total Funding

$542M

Headquarters

Menlo Park, California

Founded

2016

Get referred to Orca Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval on June 30, 2026 validates Orca Bio's platform and pipeline.
  • The company raised $250 million in December 2025, funding launch and expansion.
  • Princeton capacity and Sacramento hiring support commercialization and faster nationwide patient delivery.

What critics are saying

  • TREGZI costs $428,000, forcing transplant centers and payers into tough coverage fights.
  • Complex donor-specific manufacturing can bottleneck supply, delaying launches beyond the planned 25 centers.
  • Any post-marketing safety signal or FDA CMC issue would cripple Orca Bio's only commercial product.

What makes Orca Bio unique

  • Orca Bio's TREGZI won FDA approval on June 30, 2026, first precision cell therapy.
  • Its donor-derived regulatory T-cell design directly reduces chronic GVHD after transplant.
  • Princeton and Sacramento manufacturing create a bicoastal vein-to-vein network for personalized production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Associated Press
Jul 1st, 2026
FDA approves Tregzi, first donor immune cell therapy cutting serious transplant complications in blood cancer patients by 70%

The US Food and Drug Administration has approved Tregzi, the first regulatory T cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult blood cancer patients undergoing stem cell transplantation. The treatment uses donor-derived immune cells to help fight cancer whilst reducing the risk of chronic GVHD, a serious complication where transplanted donor cells attack the patient's body. In the PRECISION-T trial involving 187 patients, 78% of those receiving Tregzi achieved chronic GVHD-free survival at one year, compared to 38.4% receiving standard transplants. Only 12.6% of Tregzi patients developed serious chronic GVHD within one year versus 44% in the control group. The treatment, developed by Orca Biosystems, received Orphan Drug and Regenerative Medicine Advanced Therapy designations.

Fierce Pharma
Jul 1st, 2026
Orca Bio secures FDA approval for $428K cell therapy Tregzi, eyes potential IPO

Orca Bio has secured FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. The allogeneic regulatory T cell-based immunotherapy is approved as an alternative stem cell transplant to improve survival free of chronic graft-versus-host disease in adults with hematological malignancies. In the phase 3 Precision-T trial involving 187 patients, 78% who received Tregzi were alive and free from chronic GVHD at one year, compared to 38% with standard transplants—a 74% improvement. Overall survival was 94% versus 83%. Orca is pricing Tregzi at $428,000 wholesale acquisition cost. The company recently raised $250 million and is launching at select centres, aiming for 25 by year-end. CEO Nate Fernhoff said the company is "well capitalised" for launch but didn't rule out a future IPO.

Associated Press
Jun 30th, 2026
Orca Bio's TREGZI becomes first FDA-approved precision cell therapy for blood cancer transplants

Orca Bio has received US FDA approval for TREGZI, the first precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation in adults with hematological malignancies. The therapy uses donor cells to reconstitute the immune system whilst suppressing graft-versus-host disease (GVHD). The approval is based on the Phase 3 Precision-T study of 187 patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome and mixed-phenotype acute leukaemia. Results showed 78% chronic GVHD-free survival at 12 months with TREGZI compared to 38% with conventional transplant. Overall survival was 94% versus 83%, whilst non-relapse mortality was 3% compared to 13%. TREGZI is a personalised treatment manufactured for each patient using living cells from a matched donor.

San Francisco Biotechnology Network
Jun 15th, 2026
Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval.

Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. June 15, 2026 san francisco biotechnology network news news, syndication comments off on orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. Orca Bio, a biotechnology company that works in precision cell therapy, has expanded its Sacramento workforce and added an East Coast manufacturing center in Princeton, New Jersey, as it prepares for commercialization. Click here to view original post

Business Wire
Jun 15th, 2026
Orca Bio expands manufacturing for Orca-T launch with East Coast facility and tripled workforce

Orca Bio has expanded its manufacturing capabilities ahead of the potential launch of its lead cell therapy, Orca-T, adding East Coast manufacturing capacity in Princeton, New Jersey, and tripling its West Coast manufacturing workforce in Sacramento, California. The Princeton facility will serve as a strategic East Coast manufacturing bridge, initially producing therapies for ongoing clinical programmes and supporting commercial production following potential FDA approval. The bicoastal network aims to reduce "vein-to-vein" time for patients nationwide. Orca Bio has more than tripled its Sacramento operations team over the past year, enhancing expertise in manufacturing, supply chain logistics and quality assurance. Orca-T's Biologics License Application is under FDA review, with a target action date of 6 July 2026.